Related Experiment Videos
The effectiveness of surfactant replacement therapy for preterm infants with respiratory distress syndrome
Insights
Surfactant replacement therapy significantly improved outcomes for preterm infants with respiratory distress syndrome (RDS). This treatment reduced mortality rates and shortened the duration of respiratory support and nutritional therapy.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Critical Care Medicine
Background:
- Respiratory distress syndrome (RDS) is a common condition in preterm infants.
- Mechanical ventilation is often required for RDS management.
- Surfactant deficiency is a key factor in RDS pathophysiology.
Purpose of the Study:
- To evaluate the efficacy of modified bovine surfactant (Survanta) in preterm infants with RDS.
- To compare outcomes of surfactant-treated infants with historical controls.
Main Methods:
- A cohort of 30 preterm infants (birth weight >= 800 g) with RDS requiring mechanical ventilation (FiO2 >= 40%) received surfactant therapy.
- Outcomes were compared to an equal number of historical controls.
- Key parameters assessed included oxygenation, respiratory support duration, mortality, and nutritional support duration.
Main Results:
- Surfactant treatment led to significant improvements in oxygenation (FiO2, arterial/alveolar oxygen tension ratio) and reduced the ventilatory index.
- Mortality rate was significantly lower in the surfactant group (10% vs. 33%, p=0.03).
- Survivors receiving surfactant required shorter durations of CPAP, overall ventilatory support, and total parenteral nutrition, and achieved full enteral feeds sooner.
Conclusions:
- Modified bovine surfactant (Survanta) is effective in treating preterm infants with respiratory distress syndrome.
- Surfactant replacement therapy improves respiratory parameters, reduces mortality, and shortens the need for respiratory and nutritional support.
Abstract:
Thirty preterm infants weighing > or = 800 g with clinical and radiological evidence of respiratory distress syndrome (RDS) requiring mechanical ventilation with FiO2 of > or = 40% were given modified bovine surfactant (Survanta). They were compared with equal number of historical controls. Infants who received surfactant showed prompt and highly significant improvement in FiO2, mean airway pressure, arterial/alveolar oxygen tension ratio and ventilatory index. There was significant improvement in mortality rate (10% vs 33%; p = 0.03). Among the survivors, surfactant-treated infants required shorter duration of continuous positive airway pressure (CPAP) (3.4 vs 9.6 days; p = 0.04). For survivors with birthweight of > 1000 g, surfactant-treated infants required shorter duration of ventilatory support (intermittent positive pressure ventilation + CPAP) (7.5 vs 18.9 days, p = 0.02). Overall, surfactant-treated infants achieved full enteral feeds sooner (15.7 days vs 24.6 days; p = 0.03) and required shorter duration of total parenteral nutrition (13.9 days vs 25.6 days; p = 0.02). We concluded that surfactant replacement therapy was effective in the treatment of preterm infants with RDS.